首页> 外文期刊>Journal of endocrinological investigation. >microRNA-181 a promotes the oncogene S1 00A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C
【24h】

microRNA-181 a promotes the oncogene S1 00A2 and enhances papillary thyroid carcinoma growth by mediating the expression of histone demethylase KDM5C

机译:microRNA-181 a 通过介导组蛋白去甲基化酶 KDM5C 的表达来促进癌基因 S1 00A2 并增强甲状腺状癌的生长

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and purpose Papillary thyroid carcinoma (PTC) is an endocrine malignancy. Increasing evidence highlights microRNAs (miRNAs) as important participants in PTC. Here, we investigated the role of miR-181a in PTC. Methods A microarray-based analysis was performed to identify the differential expression of miR-181a in PTC, which was validated with RT-qPCR. Protein expression of the proliferation-related factor Ki-67 and apoptosis- and migration-related factors in PTC was assessed with immunoblot analysis. A dual-luciferase reporter gene assay was adopted to verify the relationship between miR-181a and lysine demethylase 5C (KDM5C). Chromatin immunoprecipitation (ChIP) was used to detect the level of the H3K4me3 modification on S100 calcium-binding protein A2 (S100A2). Cell viability, apoptosis, and invasion and migration abilities were evaluated by Cell Counting Kit-8 (CCK-8), flow cytometry, and transwell assays, respectively. The in vitro results were verified in in vivo nude mouse models. Results miR-181a was highly expressed in PTC tissues and cell lines. Silencing miR-181a repressed the proliferation and migration of PTC cells. KDM5C was identified as the target gene of miR-181a and represses S100A2 expression through histone demethylation to diminish the migration and proliferation of PTC cells. miR-181 a depletion suppressed tumor growth. Conclusion Collectively, these results suggest that highly expressed miR-181a promotes the proliferation of PTC cells by increasing the expression of the oncogene S100A2. This study contributes to the advancement of miR-181a-targeted therapeutics.
机译:背景和目的 甲状腺状癌(PTC)是一种内分泌恶性肿瘤。越来越多的证据表明 microRNA (miRNA) 是 PTC 的重要参与者。在这里,我们研究了 miR-181a 在 PTC 中的作用。方法 采用微阵列分析鉴定miR-181a在PTC中的差异表达,并通过RT-qPCR进行验证。 采用免疫印迹分析法评估PTC中增殖相关因子Ki-67的蛋白表达以及细胞凋亡和迁移相关因子的蛋白表达。采用双荧光素酶报告基因法验证miR-181a与赖氨酸去甲基化酶5C(KDM5C)的关系。染色质免疫沉淀(ChIP)检测H3K4me3修饰对S100钙结合蛋白A2(S100A2)的水平。分别通过细胞计数试剂盒-8 (CCK-8)、流式细胞术和 transwell 测定法评估细胞活力、细胞凋亡以及侵袭和迁移能力。体外结果在体内裸鼠模型中得到验证。结果 miR-181a在PTC组织和细胞系中高表达。沉默miR-181a抑制PTC细胞的增殖和迁移。KDM5C被鉴定为miR-181a的靶基因,通过组蛋白去甲基化抑制S100A2的表达,从而减少PTC细胞的迁移和增殖。miR-181 a 耗竭抑制肿瘤生长。结论 高表达miR-181a通过增加癌基因S100A2的表达来促进PTC细胞的增殖。这项研究有助于推动miR-181a靶向疗法的发展。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号